

# Philip D Dunne

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1993157/philip-d-dunne-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

56  
papers

2,550  
citations

22  
h-index

50  
g-index

67  
ext. papers

4,163  
ext. citations

8.3  
avg, IF

4.68  
L-index

#	Paper	IF	Citations
56	Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning. <i>Gut</i> , <b>2021</b> , 70, 544-554	19.2	47
55	In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 288-300	12.9	1
54	Comment on "Identification of EMT-related high-risk stage II colorectal cancer and characterisation of metastasis-related genes". <i>British Journal of Cancer</i> , <b>2021</b> , 124, 1175-1176	8.7	1
53	FLINO-A new method for immunofluorescence bioimage normalization. <i>Bioinformatics</i> , <b>2021</b> ,	7.2	2
52	Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2021</b> , 20, 1627-1639	6.1	4
51	Development of a semi-automated method for tumour budding assessment in colorectal cancer and comparison with manual methods. <i>Histopathology</i> , <b>2021</b> ,	7.3	2
50	The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer. <i>Nature Genetics</i> , <b>2021</b> , 53, 16-26	36.3	31
49	Downregulation of PPAR $\delta$ during Experimental Left Ventricular Hypertrophy Is Critically Dependent on Nox2 NADPH Oxidase Signalling. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	3
48	The pseudo-caspase FLIP(L) regulates cell fate following p53 activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2020</b> , 117, 17808-17819	11.5	10
47	Prognosis following surgical resection versus local excision of stage pT1 colorectal cancer: A population-based cohort study. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , <b>2020</b> , 18, 65-74	2.5	0
46	Exploiting differential Wnt target gene expression to generate a molecular biomarker for colorectal cancer stratification. <i>Gut</i> , <b>2020</b> , 69, 1092-1103	19.2	28
45	Defining the molecular evolution of extrauterine high grade serous carcinoma. <i>Gynecologic Oncology</i> , <b>2019</b> , 155, 305-317	4.9	8
44	The Intricate Interplay between Epigenetic Events, Alternative Splicing and Noncoding RNA Deregulation in Colorectal Cancer. <i>Cells</i> , <b>2019</b> , 8,	7.9	17
43	Fibroblast-derived Gremlin1 localises to epithelial cells at the base of the intestinal crypt. <i>Oncotarget</i> , <b>2019</b> , 10, 4630-4639	3.3	6
42	ACE: A Workbench Using Evolutionary Genetic Algorithms for Analyzing Association in TCGA. <i>Cancer Research</i> , <b>2019</b> , 79, 2072-2075	10.1	2
41	Punctate MLH1 mismatch repair immunostaining in colorectal cancer. <i>Histopathology</i> , <b>2019</b> , 74, 795-797	7.3	4
40	Prospective patient stratification into robust cancer-cell intrinsic subtypes from colorectal cancer biopsies. <i>Journal of Pathology</i> , <b>2018</b> , 245, 19-28	9.4	37

39	Validation of the systematic scoring of immunohistochemically stained tumour tissue microarrays using QuPath digital image analysis. <i>Histopathology</i> , <b>2018</b> , 73, 327-338	7.3	27
38	Epithelial-to-mesenchymal transition signature assessment in colorectal cancer quantifies tumour stromal content rather than true transition. <i>Journal of Pathology</i> , <b>2018</b> , 246, 422-426	9.4	14
37	as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in -mutant stage II and III colon cancer. <i>Oncotarget</i> , <b>2018</b> , 9, 13834-13847	3.3	4
36	Transcriptional subtyping and CD8 immunohistochemistry identifies poor prognosis stage II/III colorectal cancer patients who benefit from adjuvant chemotherapy. <i>JCO Precision Oncology</i> , <b>2018</b> , 2018,	3.6	31
35	Impact of Variable RNA-Sequencing Depth on Gene Expression Signatures and Target Compound Robustness: Case Study Examining Brain Tumor (Glioma) Disease Progression. <i>JCO Precision Oncology</i> , <b>2018</b> , 2,	3.6	3
34	Stromal Cell PD-L1 Inhibits CD8 T-cell Antitumor Immune Responses and Promotes Colon Cancer. <i>Cancer Immunology Research</i> , <b>2018</b> , 6, 1426-1441	12.5	37
33	Signalling mechanisms underlying doxorubicin and Nox2 NADPH oxidase-induced cardiomyopathy: involvement of mitofusin-2. <i>British Journal of Pharmacology</i> , <b>2017</b> , 174, 3677-3695	8.6	25
32	Back to the future: routine morphological assessment of the tumour microenvironment is prognostic in stage II/III colon cancer in a large population-based study. <i>Histopathology</i> , <b>2017</b> , 71, 12-26	7.3	36
31	Response to Park et al. reply to SBack to the future: routine morphological assessment of the tumour microenvironment is prognostic in stage II/III colon cancer in a large population-based studyS <i>Histopathology</i> , <b>2017</b> , 71, 327-329	7.3	1
30	Gremlin1 plays a key role in kidney development and renal fibrosis. <i>American Journal of Physiology - Renal Physiology</i> , <b>2017</b> , 312, F1141-F1157	4.3	40
29	Natural killer-like signature observed post therapy in locally advanced rectal cancer is a determinant of pathological response and improved survival. <i>Modern Pathology</i> , <b>2017</b> , 30, 1287-1298	9.8	14
28	Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies. <i>British Journal of Cancer</i> , <b>2017</b> , 117, 203-209	8.7	27
27	Standardising RNA profiling based biomarker application in cancer-The need for robust control of technical variables. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , <b>2017</b> , 1868, 258-272	11.2	12
26	Cancer-cell intrinsic gene expression signatures overcome intratumoural heterogeneity bias in colorectal cancer patient classification. <i>Nature Communications</i> , <b>2017</b> , 8, 15657	17.4	45
25	Intratumoural Epigenetic Heterogeneity in Early Invasive Colorectal Cancer: APrognostic Imprint?. <i>Gastroenterology</i> , <b>2017</b> , 152, 1622-1623	13.3	2
24	Embracing an integromic approach to tissue biomarker research in cancer: Perspectives and lessons learned. <i>Briefings in Bioinformatics</i> , <b>2017</b> , 18, 634-646	13.4	6
23	IHC-based subcellular quantification provides new insights into prognostic relevance of FLIP and procaspase-8 in non-small-cell lung cancer. <i>Cell Death Discovery</i> , <b>2017</b> , 3, 17050	6.9	3
22	QuPath: Open source software for digital pathology image analysis. <i>Scientific Reports</i> , <b>2017</b> , 7, 16878	4.9	1369

21	Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer. <i>British Journal of Cancer</i> , <b>2017</b> , 117, 347-352	8.7	22
20	KRAS mutant colorectal cancer gene signatures identified angiotensin II receptor blockers as potential therapies. <i>Oncotarget</i> , <b>2017</b> , 8, 3206-3225	3.3	7
19	EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 230-242	12.9	73
18	QUADrATiC: scalable gene expression connectivity mapping for repurposing FDA-approved therapeutics. <i>BMC Bioinformatics</i> , <b>2016</b> , 17, 198	3.6	21
17	Transcriptional upregulation of c-MET is associated with invasion and tumor budding in colorectal cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 78932-78945	3.3	31
16	Stratified analysis reveals chemokine-like factor (CKLF) as a potential prognostic marker in the MSI-immune consensus molecular subtype CMS1 of colorectal cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 36632-36644	3.3	10
15	Immune-Derived PD-L1 Gene Expression Defines a Subgroup of Stage II/III Colorectal Cancer Patients with Favorable Prognosis Who May Be Harmed by Adjuvant Chemotherapy. <i>Cancer Immunology Research</i> , <b>2016</b> , 4, 582-91	12.5	31
14	Challenging the Cancer Molecular Stratification Dogma: Intratumoral Heterogeneity Undermines Consensus Molecular Subtypes and Potential Diagnostic Value in Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 4095-104	12.9	88
13	PICan: An integromics framework for dynamic cancer biomarker discovery. <i>Molecular Oncology</i> , <b>2015</b> , 9, 1234-40	7.9	13
12	Connectivity mapping using a combined gene signature from multiple colorectal cancer datasets identified candidate drugs including existing chemotherapies. <i>BMC Systems Biology</i> , <b>2015</b> , 9 Suppl 5, S4	3.5	14
11	The prognostic value of the stem-like group in colorectal cancer using a panel of immunohistochemistry markers. <i>Oncotarget</i> , <b>2015</b> , 6, 12763-73	3.3	14
10	AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 164-75	12.9	83
9	Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer. <i>Cell Death and Disease</i> , <b>2014</b> , 5, e1046	9.8	68
8	ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer. <i>Cell Reports</i> , <b>2014</b> , 7, 1940-55	10.6	74
7	cudaMap: a GPU accelerated program for gene expression connectivity mapping. <i>BMC Bioinformatics</i> , <b>2013</b> , 14, 305	3.6	21
6	Connectivity Mapping for Candidate Therapeutics Identification Using Next Generation Sequencing RNA-Seq Data. <i>PLoS ONE</i> , <b>2013</b> , 8, e66902	3.7	13
5	Pharmacogenomic profiling and pathway analyses identify MAPK-dependent migration as an acute response to SN38 in p53 null and p53-mutant colorectal cancer cells. <i>Molecular Cancer Therapeutics</i> , <b>2012</b> , 11, 1724-34	6.1	7
4	DNMT1 deficiency triggers mismatch repair defects in human cells through depletion of repair protein levels in a process involving the DNA damage response. <i>Human Molecular Genetics</i> , <b>2011</b> , 20, 3241-55	5.6	50

3	QuPath: Open source software for digital pathology image analysis	8
2	Bcl-xL as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in BRAF-mutant stage II and III colon cancer	1
1	Stromal cell sialylation suppresses T cells in inflammatory tumour microenvironments: A new tumour stromal cell immune checkpoint?	1